| HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NA | Avapritinib | Ayvakit | 50mg | Chemotherapy | Tyrosine Kinase Inhibitor | PDGFR, KIT, CSFR1 | Yes | 2020 | In Use | |||
| C9069 | Belantamab mafodotin-blmf | Blenrep | 0.5mg | Immunotherapy | Drug Antibody Conjugate | BCMA | No | 2020 | Jan 1, 2021 | No Longer Used | ||
| Mobocertinib | Exkivity | 40mg | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Yes | 2021 | In Use | ||||
| Q5112 | Trastuzumab-dttb | Ontruzant | 10mg | Immunotherapy | Monoclonal Antibody | HER2 | No | 2021 | Jul 1, 2019 | In Use | ||
| J9021 | Asparaginase Erwinia Chrysanthemi (recombinant)-rywn | Rylaze | 0.1mg | Chemotherapy | Miscellaneous Agent | Enzyme | No | 2021 | Jan 26, 2022 | In Use | ||
| Q2054 | Lisocabtagene maraleucel | Breyanzi | Immunotherapy | CAR-T | CD19 | No | 2021 | Sep 27, 2021 | In Use | |||
| Q5123 | Rituximab-arrx | Riabni | 10mg | Immunotherapy | Monoclonal Antibody | CD20 | No | 2021 | Jul 23, 2021 | In Use | ||
| NA | Tivozanib | Fotivda | 0.89mg, 1.34mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Yes | 2021 | In Use | |||
| C9087 | Cyclophosphamide (Auromedics) | Cyclophosphamide | 10mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 2021 | Jan 26, 2022 | Mar 25, 2022 | No Longer Used | |
| Q2055 | Idecabtagene vicleucel | Abecma | 460 million | Immunotherapy | CAR-T | BCMA | No | 2021 | Jan 26, 2022 | In Use | ||
| BA | Belzutifan | Welireg | 40mg | Chemotherapy | Miscellaneous Agent | HIF-2 alpha | Yes | 2021 | In Use | |||
| NA | Umbralisib | Ukoniq | 260.2mg | Chemotherapy | Enzyme Inhibitor | PI3Kδ, CK1ε, ABL1, CXCL12, CCL19 | Yes | 2021 | In Use | |||
| J9071 | Cyclophosphamide (AuroMedics) | Cyclophosphamide | 5mg | Chemotherapy | Alkylating Agent | Nitrogen mustard | No | 2021 | Mar 25, 2022 | In Use | ||
| J1448 | Trilaciclib | Cosela | 1mg | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | No | 2021 | Sep 27, 2021 | In Use | ||
| J1932 | Lanreotide (Cipla) | Lanreotide Acetate | 1mg | Hormonal Therapy | Somatostatin Analog | No | 2021 | Sep 27, 2022 | In Use | |||
| C9078 | Trilaciclib | Cosela | 1mg | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDX 4/6 | No | 2021 | Jul 23, 2021 | Sep 27, 2021 | No Longer Used | |
| Infigratinib | Truseltiq | Multiple | Chemotherapy | Tyrosine Kinase Inhibitor | FGFR | Yes | 2021 | In Use | ||||
| NA | Tepotinib Hydrochloride | Tepmetko | 225mg | Chemotherapy | Tyrosine Kinase Inhibitor | MET | Yes | 2021 | In Use | |||
| J9247 | Melphalan flufenamide | Pepaxto | 1mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 2021 | Sep 27, 2021 | Mar 26, 2025 | No Longer Used | |
| C9081 | Idecabtagene vicleucel | Abecma | up to 460000000 | Immunotherapy | CAR-T | BCMA | No | 2021 | Sep 27, 2021 | Jan 26, 2022 | No Longer Used | |
| C9084 | Loncastuximab tesirine | Zylonta | 0.1mg | Immunotherapy | Drug Antibody Conjugate | CD19 | No | 2021 | Sep 27, 2021 | Mar 25, 2022 | In Use | |
| J9272 | Dostarlimab-gxly | Jemperli | 10mg | Immunotherapy | Checkpoint Inhibitor | PD-1 | No | 2021 | Jan 26, 2022 | In Use | ||
| J1952 | Leuprolide Mesylate | Camcevi | 1mg | Hormonal Therapy | GnRH Agonist | No | 2021 | Jan 26, 2022 | In Use | |||
| C9082 | Dostarlimab-gxly | Jemperli | 100mg | Immunotherapy | Checkpoint Inhibitor | PD-1 | No | 2021 | Sep 27, 2021 | Jan 26, 2022 | No Longer Used | |
| J9061 | Amivantamab | Rybrevant | 2mg | Immunotherapy | Monoclonal Antibody | EGFR, MET | No | 2021 | Jan 26, 2022 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.
Home